SCHEMBL6401375

SCHEMBL6401375

COc1ccc(NS(=O)(=O)CN(CCCc2ccccc2)C(=O)CC(C)CCNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
GAA P10253 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
MMP3 P08254 6/20 0.39
MMP1 P03956 6/20 0.39
MMP2 P08253 5/20 0.39
PDE4A P27815 4/20 0.39
PDE4B Q07343 4/20 0.39
PDE4C Q08493 4/20 0.39
PDE4D Q08499 4/20 0.39
MMP9 P14780 3/20 0.38
SIGMAR1 Q99720 2/20 0.38
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALOX5 P09917 1/20 0.37
PLAAT3 P53816 1/20 0.36
PLAAT5 Q96KN8 1/20 0.36
PLAAT2 Q9NWW9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403180 0.90 MMP3 (0.42) NPC1RAB9AGAATAAR1MMP3
SCHEMBL6407167 0.90 CA1 (0.42) NPC1RAB9AGAATAAR1MMP3
SCHEMBL6404812 0.89 NPC1 (0.40) NPC1RAB9ASIGMAR1LMNASMN1; SMN2
SCHEMBL6401317 0.84 NPC1 (0.47) NPC1RAB9ASIGMAR1ALDH1A1LMNA
SCHEMBL6401362 0.84 RAB9A (0.45) NPC1RAB9AMMP3MMP1MMP2
SCHEMBL6405210 0.82 NPC1 (0.43) NPC1RAB9ASIGMAR1ALDH1A1LMNA
SCHEMBL6409464 0.82 ALOX5 (0.42) MMP3MMP1MMP2PDE4APDE4B
SCHEMBL6409458 0.82 NPC1 (0.42) NPC1RAB9ASIGMAR1LMNASMN1; SMN2
SCHEMBL6403175 0.81 L3MBTL1 (0.45) RAB9AMMP3MMP1MMP2PDE4A
SCHEMBL6401373 0.79 MMP3 (0.40) GAAMMP3MMP1MMP2PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 NPC1 972/4885RAB9A 2791/4885GAA 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.